A Phase 2 interventional study of Immune Globulin Intravenous [Human], 10% Caprylate/Chromatography Purified and Albumin (Human) 25%, United States Pharmacopeia (USP) in Macular Degeneration, sponsored by Grifols Therapeutics LLC. Completed at 7 sites in Germany. Open to participants aged 51 Years and older. Per ClinicalTrials.gov, last updated 2016-03-21.
Sponsored by Grifols Therapeutics LLC (part of Grifols) · Phase 2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 110 studies in Macular Degeneration with a site in Germany — 16 open to participants now, 24 under way, 11 of them phase 3. Macular Degeneration · Germany.
Among the 110 studies in Macular Degeneration with a site in Germany, this one is the 65th largest by enrollment of the 85 interventional ones that give a count, is one of 2 that started in 2004, is one of 20 in phase 2, and was the 2nd registered.
1,461 studies on the registry are indexed under Macular Degeneration; 237 are open to participants now.
Browse Macular Degeneration studies →16 of the 110 studies in Macular Degeneration with a site in Germany are open now. Recruiting first, the newest first:
EyeBiotech Ltd. · Sites in Germany, United States, Argentina and 9 more countries
Ages 50+
Novartis Pharmaceuticals · Sites in Germany, United States, Argentina and 16 more countries
Ages 50+
Maximilian Pfau · Sites in Germany
Ages 18+ · Healthy volunteers
Hoffmann-La Roche · Sites in Germany, Austria, Czechia and 10 more countries
Ages 50+
ADARx Pharmaceuticals, Inc. · Sites in Germany, United States, Australia and 9 more countries
Ages 60+
A study can be open while its sites in Germany have not opened yet or have stopped. Only those recruiting at a site in Germany →
Of the 166 Macular Degeneration studies recruiting now, 117 (70%) set no upper age limit and 5 (3%) stop at 75 or younger; 19 take children under 18; 35 take healthy volunteers.
This study: 51 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
110 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 2 24 · Phase 3 40 · Phase 4 15
First in 1998; this study’s year is marked. 2 started in 2004.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 96 is above the median of 56 across 986 interventional studies indexed under Macular Degeneration.
Median enrollment 274 across the 85 interventional studies, 554 across the 25 observational. Of the 79 that completed or were terminated, 45 (57%) have results posted.
This tab as a report to print or save as PDF → With an account.
84 of 110 have an industry lead sponsor. The 10 most frequent:
This study is registered under Grifols Therapeutics LLC, one of the names counted as Grifols. Under that name alone:
Grifols Therapeutics LLC is the lead sponsor of 46 studies on the registry; 4 are open to participants now.
Of its 13 completed or terminated interventional studies of FDA-regulated products, 13 (100%) have results posted.
Grifols has 4 studies filed under Macular Degeneration — fewer than ten, so there is no comparison to draw.
7 of the studies in Macular Degeneration with a site in Germany that are under way reach primary completion within a year, 3 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT04657289Phase 3Hoffmann-La RocheA Study of the Efficacy, Safety, and Pharmacokinetics of a 36-Week Refill Regimen for the Port Delivery System With Ranibizumab in Patients With Neovascular Age-Related Macular Degeneration (Velodrome) | 2027-02-04 |
| NCT06373731Phase 3Stealth BioTherapeutics Inc.ReNEW:Phase 3 Study of Efficacy, Safety & Pharmacokinetics of Subcutaneous Injections of Elamipretide in Subjects With Dry Age-Related Macular Degeneration (Dry AMD) | 2027-08 |
| NCT07064759Phase 34D Molecular TherapeuticsSingle Intravitreal (IVT) Injection of 4D-150 in Patients With Macular Neovascularization Secondary to Age-Related Macular Degeneration | 2027-11 |
| NCT07164378VisionCare, Inc.International Study of the SING IMT™ Prosthesis in Pseudophakic patiEnts With Stable Moderate to Profound Bilateral Central vIsion Impairment Due to adVancEd AMD / PERSPECTIVE Study | 2026-12-30 |
| NCT04796545VisionCare, Inc.Post-market Clinical Investigation of the SING IMT System, Model NG SI IMT 3X in Patients With End-stage Age-related Macular Degeneration | 2027-05 |
Add all 7 to your calendar (.ics) → With an account.
Among the 110 studies in Macular Degeneration with a site in Germany, from their registry updates:
This tab as a report to print or save as PDF → With an account.
This study will evaluate visual improvement in patients treated with Immune Globulin Intravenous (Human), 10% Caprylate/Chromatography Purified (IGIV-C) or placebo who have Age-Related Macular Degeneration (AMD) with occult Choroidal Neovascularization (CNV).
The purpose of this trial is to investigate the effect of IGIV-C in subjects suffering from AMD with occult CNV where fewer treatment options exist for patients with this disease form.
This study is designed as a randomized, double-blind, parallel group, placebo-controlled prospective trial. Sixty patients, 30 per treatment group, with newly diagnosed pure occult CNV defined by angiography diagnostic criteria will be enrolled. If a subject has more than one eye affected with occult CNV, the eye with the better vision as measured by visual acuity ( Logarithm of the Minimum Angle of Resolution [LogMAR] score) will be entered as the study eye.
Patients will be randomized to receive either IGIV-C at a dose of 2 g/kg body weight (bw) over 5 consecutive days or matching placebo. Additional 2 study drug treatment courses (IGIV-C or matching placebo) will be administered every 4 weeks at the same dose of 2 g/kg bw given over 5 days. Subjects' visual acuity will be measured and reported as LogMAR at screening, week 0 (baseline), day 5, week 4, week 8 and week 12. If at anytime during the study the subject's visual acuity worsens by ≥ 2 lines (0.2 on the LogMAR score), then a slit lamp examination will be performed and an angiogram will be conducted; the patient would be discontinued if the worsening is due to some other reason outside of the occult CNV or if the disease has changed from pure occult to the classic or mixed form.
Subjects will be evaluated for efficacy (LogMAR score) at endpoint (at week 12 or at last LogMAR assessment at or after week 8, if the subject prematurely discontinues the trial).
At the end of the treatment period (week 12), patients will be entered into a 3 month observation period with monthly visual acuity LogMAR score assessments.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
The New York Heart Association’s four classes of how much heart failure limits physical activity.
Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
NYHA class (heart failure)
The New York Heart Association’s four classes of how much heart failure limits physical activity.
Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Childbearing potential
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Corticosteroids (steroids)
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hypersensitivity
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Drug: Immune Globulin Intravenous [Human], 10% Caprylate/Chromatography Purified
Drug: Albumin (Human) 25%, United States Pharmacopeia (USP)
Drug page: Immunoglobulins, Intravenous
The dose per infusion cycle was 2 g/kg body weight over 5 consecutive days (= 4 mL/kg body weight/infusion). The infusion duration was approximately 1.5 - 2 h.
Also known as: Gamunex®, IGIVnex®, Gaminex, IGIV-C, IGIV-C, 10%, Immune Globulin IV (Human), 10% (IGIV), Immune Globulin IV (Human), 10% by Chromatography Process, IGIV, IVIG, BAY 41-1000, TAL-05-00004, NDC 13533-645-12, NDC 13533-645-15, NDC 13533-645-20, NDC 13533-645-24, NDC 13533-645-71
Albumin (Human) 20% or 25% will be diluted with 5% glucose to a final concentration of 0.1%.
Also known as: Plasbumin®-20, Plasbumin®-25, Plasbumin®-20 (Low Aluminum), Plasbumin®-25 (Low Aluminum), Albumin (Human) 20%, USP, TAL-05-00007, TAL-05-00008, TAL-05-00024, TAL-05-00025, BAY 34-9255, NDC 13533-683-20, NDC 13533-683-71, NDC 13533-684-16, NDC 13533-684-20, NDC 13533-684-71, NDC 13533-691-20, NDC 13533-691-71, NDC 13533-692-16, NDC 13533-692-20, NDC 13533-692-71
Mean Change in Visual Acuity (Logarithm of the Minimum Angle of Resolution [LogMAR]) Score From Baseline for IGIV-C, 10% Compared to Placebo at Week 12 or at Last LogMAR Assessment (Conducted at or After Week 8 of the Treatment Period)
Using the LogMAR score, lower values correspond to higher visual acuity. For example, a visual acuity of 20/20 corresponds to a LogMAR value of zero (0), and a visual acuity of 20/100 corresponds to a LogMAR value of 0.7.
Time frame: At Week 12 or, if the Week 12 assessment is not available, at the last LogMAR assessment conducted at or after Week 8 of the Treatment Period
Proportion of Subjects Who Improve Visual Acuity From Baseline to Endpoint by ≥ 0.1 LogMAR
Time frame: Last measurement at or later than Week 8
Proportion of Subjects Who Improve Visual Acuity From Baseline to Endpoint by ≥ 0.2 LogMAR
Time frame: Last measurement at or later than Week 8
Mean Change in LogRAD Score From Baseline to Endpoint (RADNER Test)
The RADNER test gives not only information about the subject's reading performance, but also about the reading speed (life quality) and the faults while reading. The RADNER reading charts (1, 2, and 3) contain sentences in paragraphs having a range of print sizes starting with the largest print at the top.The subject was randomly assigned one of the RADNER charts, and the charts were different between consecutive visits. The reading distance was 25 cm. The subject's score was corrected for reading speed and errors. The range of possible logRAD scores was from 2.0 (could not read the first paragraph) to -0.2, with higher scores indicating lower reading acuity and lower scores indicating higher reading acuity.
Time frame: Last measurement at or later than Week 8
Proportion of Subjects With an Increase ≥ 2 or More Points in Lens Opacity Classification System (LOCS III) for Nuclear Opalescence, Nuclear Color, Cortical Cataract or Posterior Subcapsular Cataract Categories
The LOCS III scale for cortical cataract and posterior subcapsular cataract opacity ranged from 1.0 to 5.0. The LOCS III scale for nuclear opalescence and for nuclear color was 1.0 to 6.0. For all scales, higher values indicate higher opacity, opalescence, or color.
Time frame: Last measurement at or later than Week 8
Presence of Fibrosis and Location Assessed by Slit-lamp
Time frame: Last measurement at or later than Week 8
Mean Change From Baseline to Endpoint in Size of Lesion (Largest Dimension Relative to Disk Diameter) Assessed by Central Fluorescein Angiogram Reading Center
Time frame: At end of treatment (12 weeks)
A total of 96 subjects were enrolled (signed the informed consent and screened) in this study at 6 German study centers.
| Milestone | IGIV-C 10% | Placebo |
|---|---|---|
| Started | 30 | 27 |
| Completed | 22 | 16 |
| Not completed | 8 | 11 |
| Withdrew: Adverse event | 1 | 3 |
| Withdrew: Withdrawal by subject | 3 | 0 |
| Withdrew: Lack of efficacy | 1 | 0 |
| Withdrew: Develop. of choroidal neovascularization | 3 | 8 |
Using the LogMAR score, lower values correspond to higher visual acuity. For example, a visual acuity of 20/20 corresponds to a LogMAR value of zero (0), and a visual acuity of 20/100 corresponds to a LogMAR value of 0.7.
| LogMAR | IGIV-C 10% | Placebo |
|---|---|---|
| Baseline | 0.581 ± 0.209 | 0.533 ± 0.153 |
| End of treatment (EOT) Week 12 or last assessment | 0.646 ± 0.309 | 0.557 ± 0.244 |
| Change End of treatment (EOT) minus Baseline | 0.064 ± 0.220 | 0.024 ± 0.182 |
| percentage of participants | IGIV-C 10% | Placebo |
|---|---|---|
| Proportion of Subjects Who Improve Visual Acuity From Baseline to Endpoint by ≥ 0.1 LogMAR | 24.1 | 20.8 |
| percentage of participants | IGIV-C 10% | Placebo |
|---|---|---|
| Proportion of Subjects Who Improve Visual Acuity From Baseline to Endpoint by ≥ 0.2 LogMAR | 3.4 | 16.7 |
The RADNER test gives not only information about the subject's reading performance, but also about the reading speed (life quality) and the faults while reading. The RADNER reading charts (1, 2, and 3) contain sentences in paragraphs having a range of print sizes starting with the largest print at the top.The subject was randomly assigned one of the RADNER charts, and the charts were different between consecutive visits. The reading distance was 25 cm. The subject's score was corrected for reading speed and errors. The range of possible logRAD scores was from 2.0 (could not read the first paragraph) to -0.2, with higher scores indicating lower reading acuity and lower scores indicating higher reading acuity.
| LogRAD | IGIV-C 10% | Placebo |
|---|---|---|
| Mean Change in LogRAD Score From Baseline to Endpoint (RADNER Test) | 0.164 ± 0.343 | 0.159 ± 0.371 |
The LOCS III scale for cortical cataract and posterior subcapsular cataract opacity ranged from 1.0 to 5.0. The LOCS III scale for nuclear opalescence and for nuclear color was 1.0 to 6.0. For all scales, higher values indicate higher opacity, opalescence, or color.
| participants | IGIV-C 10% | Placebo |
|---|---|---|
| Proportion of Subjects With an Increase ≥ 2 or More Points in Lens Opacity Classification System (LOCS III) for Nuclear Opalescence, Nuclear Color, Cortical Cataract or Posterior Subcapsular Cataract Categories | 0 | 0 |
| participants | IGIV-C 10% | Placebo |
|---|---|---|
| Presence of Fibrosis and Location Assessed by Slit-lamp | 1 | 3 |
| Disk Diameter | IGIV-C 10% | Placebo |
|---|---|---|
| Mean Change From Baseline to Endpoint in Size of Lesion (Largest Dimension Relative to Disk Diameter) Assessed by Central Fluorescein Angiogram Reading Center | 0.074 ± 0.209 | 0.173 ± 0.298 |
Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| IGIV-C 10% | — | 1/30 (3.3%) | 21/30 (70%) |
| Placebo | — | 5/27 (18.5%) | 15/27 (55.6%) |
| Event | IGIV-C 10% | Placebo |
|---|---|---|
| Cerebrovascular accidentNervous system disorders | 0/30 | 1/27 |
| Transient ischemic attackNervous system disorders | 0/30 | 1/27 |
| CholelithiasisHepatobiliary disorders | 0/30 | 1/27 |
| Abdominal pain, upperGastrointestinal disorders | 0/30 | 1/27 |
| Brain neoplasmNeoplasms benign, malignant and unspecified (incl cysts and polyps) | 0/30 | 1/27 |
| Stent placementSurgical and medical procedures | 1/30 | 0/27 |
| Event | IGIV-C 10% | Placebo |
|---|---|---|
| NauseaGastrointestinal disorders | 2/30 | 3/27 |
| Blood pressure increasedInvestigations | 2/30 | 3/27 |
| Abdominal pain, upperGastrointestinal disorders | 0/30 | 2/27 |
| Blood urea increasedInvestigations | 2/30 | 2/27 |
| CoughRespiratory, thoracic and mediastinal disorders | 1/30 | 2/27 |
| PruritisSkin and subcutaneous tissue disorders | 0/30 | 2/27 |
| VertigoEar and labyrinth disorders | 2/30 | 1/27 |
| FatigueGeneral disorders | 2/30 | 0/27 |
| CystitisInfections and infestations | 2/30 | 0/27 |
| Hand fractureInjury, poisoning and procedural complications | 2/30 | 0/27 |
The intent to treat (ITT) population, which was defined as the primary analysis population, comprised 29 subjects treated with IGIV-C 10% and 24 subjects treated with placebo. A total of 4 subjects were excluded from the ITT population: 1 from IGIV-C 10% and 3 from Placebo.
| Age, Categorical(Participants) | IGIV-C 10% | Placebo | Total |
|---|---|---|---|
| <=18 years | 0 | 0 | 0 |
| Between 18 and 65 years | 4 | 4 | 8 |
| >=65 years | 25 | 20 | 45 |
| Age, Continuous(years) | IGIV-C 10% | Placebo | Total |
|---|---|---|---|
| Mean | 74.724 ± 8.417 | 74.042 ± 10.217 | 74.415 ± 9.189 |
| Sex: Female, Male(Participants) | IGIV-C 10% | Placebo | Total |
|---|---|---|---|
| Female | 20 | 17 | 37 |
| Male | 9 | 7 | 16 |
| Region of Enrollment(participants) | IGIV-C 10% | Placebo | Total |
|---|---|---|---|
| Germany | 29 | 24 | 53 |
| Visual Acuity Score (VAS) of the Study Eyes(units on a scale) | IGIV-C 10% | Placebo | Total |
|---|---|---|---|
| Mean | 55.9 ± 10.4 | 58.4 ± 7.7 | 57.0 ± 9.3 |
| Logarithm of the Minimum Angle of Resolution (LogMAR) of the Study Eyes(LogMAR) | IGIV-C 10% | Placebo | Total |
|---|---|---|---|
| Mean | 0.581 ± 0.209 | 0.533 ± 0.153 | 0.559 ± 0.186 |
The record gives a start of Jan 2004, a primary completion of May 2005 and a completion of May 2005. It does not say whether these dates are actual or estimated.
Results were first posted in Mar 2016, 10 years 10 months after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Feb 2016. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Immunoglobulins, Intravenous